Revenue segments as reported by the company.

Smokeable Products

Oral Tobacco Products

Wine

All Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, administration and research costs

Asset impairment and exit costs

Amortization of intangibles

General corporate expenses

Corporate asset impairment and exit costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Altria

Altria Group, Inc. operates as a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral tobacco products, and Wine. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral tobacco products segment is primarily moist smokeless tobacco products (MSTs) through brands like Copenhagen and Skoal as well as on! oral nicotine pouches sold by Helix. The Wine segment, through subsidiary Ste. Michelle Wine Estates Ltd, produces Washington State wines, primarily Chateau Ste. Michelle and 14 Hands, and owns wineries in or distributes wines from several other wine regions. The company was founded in 1919 and is headquartered in Richmond, VA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Altria reports robust Q4 earnings, focuses on innovation and growth

Altria's Q4 2022 performance reflects resilience amidst industry challenges, with a focus on innovation and shareholder returns. The company's strategic initiatives in smoke-free products and digital engagement underscore its commitment to long-term growth and harm reduction.

Altria reports resilient Q1 performance amid industry challenges and opportunities

Altria's Q1 2023 earnings call highlighted strong performance amidst industry challenges, emphasizing harm reduction and regulatory compliance. The company faces hurdles from inflation, regulatory changes, and evolving consumer behaviors, while focusing on growth opportunities in smoke-free products and strategic investments.

Altria reports solid Q2 earnings, eyes e-vapor growth opportunities

Altria's focus on smoke-free products and NJOY acquisition driving growth.
Challenges in the cigarette industry due to economic pressures and flavor bans.
Opportunities in the e-vapor category and expansion plans in the U.S.
Strong balance sheet and significant capital returns to shareholders.

Altria reports growth in earnings, navigates regulatory challenges in e-vapor

Altria's Q3 2023 earnings call highlighted solid financial performance, strategic focus on e-vapor products, and efforts to combat illegal vape products. The company faces challenges from regulatory uncertainties and illicit products but sees opportunities in expanding NJOY's reach and addressing market gaps.

Altria reports growth in smoke-free products amidst regulatory challenges

Altria's Q4 2023 earnings call highlighted growth in adjusted EPS, strategic focus on smoke-free products, and efforts to combat illicit e-vapor products. The company faces challenges in competitive segments and economic pressures but sees opportunities in new product introductions and regulatory collaborations.

Altria reports mixed Q1 performance, focuses on growth strategies

Altria's Q1 performance showed growth in NJOY and oral tobacco segments, with challenges in EPS decline and economic pressures on consumers.
Strengths include reaffirmed EPS guidance, strategic investments, and focus on combating illicit e-vapor products.
Opportunities lie in maximizing profitability in oral tobacco, product positioning, and capturing transitioning consumers.
Overall, Altria's performance reflects a mix of growth, challenges, and strategic opportunities in navigating market dynamics.

Altria's NJOY drives growth as company navigates e-vapor challenges

Altria's Q2 2024 earnings call showcased strong performance in smoke-free products, highlighting growth in retail share and volume momentum. Despite challenges in the e-vapor category, the company remains focused on responsible regulation and enforcement. With a commitment to shareholder value and long-term growth strategies, Altria is poised for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Altria Group, Inc. is a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral Tobacco Products, and All Other. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral Tobacco Products segment includes MST and snus products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix. The All Other segment refers to the financial results of NJOY, Helix ROW, and the IQOS System heated tobacco business. The company was founded in 1919 and is headquartered in Richmond, VA.

British American Tobacco

Philip Morris

Shares of the big three tobacco stocks continued trading lower after Nielsen data published Tuesday showed a drop in cigarette sales for the four-week period ended May 18.

Tobacco Stocks Trading Lower After Nielsen Data Shows Drop in Cigarette Sales

Tobacco stocks slid Tuesday after new Nielsen data showed cigarette sales volumes declined 11.2% in the past month, according to Nielsen.

Tobacco stocks tumble as cigarette sales decline

Altria (MO) reported earnings 30 days ago. What's next for the stock?

Altria (MO) Up 1.9% Since Last Earnings Report: Can It Continue?

There is enough support to carry MO through bad news.

Collect Income on Altria While it’s Down

Juul Labs is opening its books to overseas investors as it looks to raise cash ahead of a global growth spurt, The Post has learned.

Juul Labs quietly considering overseas financing round

Almost half of the people who followed Juul Labs Inc on Twitter last year were not old enough to legally purchase e-cigarettes in the United States, according to a study published on Monday.

Most of Juul’s Twitter followers are teens who can’t buy e-cigs

Twitter

(Reuters Health) - Almost half of the people who followed Juul Labs Inc on Twitter were not old enough to legally purchase e-cigarettes in the United States, according a study published on Monday.

Nearly half of Juul's Twitter followers are too young to buy e-cigarettes: study

Novartis

Constellation Brands

Forget the volatile marijuana stocks. Their partners could be a better and safer investment for most investors.

3 Ways to Buy Into the Marijuana Boom Without the Risk

Despite criticisms that it’s helping promote an “epidemic” in teen vaping, e-cigarette maker Juul continues to attract new investors, The Post has learned.

JUUL e-cigarette maker sees its valuation top $38B

Altria shareholders grilled CEO Howard Willard on his $12.8 billion bet on e-cigarette giant Juul at the company's annual shareholder meeting Thursday.

Investors grill Altria CEO over $12.8 billion bet on e-cigarette giant Juul

Aurora Cannabis

Cronos Group

Though perfectly legal, these accounting tricks are masking the true operating results of many pot stocks.

3 Ways Marijuana Stocks Are Tricking Investors

Stocks with juicy yields can lead to great cash flows for investors. Which of these tobacco giants is the dividend winner?

Better Dividend Stock -- Altria vs. British American Tobacco

A push by makers of electronic cigarettes to raise nicotine levels in the European Union towards their far higher American levels is running into opposition, a senior executive at U.S. market leader Juul said on Tuesday.

Vaping companies facing European opposition to higher nicotine level

I will discuss what the FDA's recent approval of IQOS means for the company.

Altria: A Strong Buy On The FDA's Comments And Decision On IQOS

Q1 2019 earnings release and guidance confirm market trends and Altria's strategy going forward.

Altria: Reducing Costs And Making Progress

iQOS is currently available in more than 40 markets around the world. It's a key component of Philip Morris' future as the company tries to pivot past cigarettes.

FDA clears Philip Morris' iQOS, paving the way for Altria to sell the heated tobacco device in US

Here's the latest thinking from the tobacco giant's executives.

Altria Keeps Mum on Marijuana Details -- for Now

I will review Altria's recent earnings report.

Time To Buy Altria - IQOS Will Eventually Be Approved By The FDA

Ford Motor Company

GlaxoSmithKline

Invesco

AT&T

Even though the economy clocked in a stunning 3.2% gross domestic product in the first quarter, way above estimates, and earnings mostly have been solid, there are warnings signs.

5 Total Return Stocks to Buy Now That All Pay 5% or Higher Dividends

Home Depot

Starbucks

These three familiar brands have made their more patient stockholders rich.

3 Consumer Goods Stocks That Turned $10,000 Into $1 Million or More

Analysts continue to pile on Cronos with negative views. Don't overlook these potential catalysts for the pot stock, though.

Everybody's Hating on Cronos Group -- but Here Are 3 Reasons the Pot Stock Could Double

The tobacco giant is preparing to convert its nonvoting shares into voting stock.

Altria Wants Greater Control Over Juul's Future

We were mildly bullish on Altria last we wrote on it.

Altria: For Whom The Smoke Blows, An Ernest Review

The cigarette giant suffered from massive sales-volume declines that sent both revenue and profit lower.

Altria's Growth Goes Up in Smoke

Xilinx

Poor earnings sent these and many other stocks lower.

News for Altria Stock (MO)